APA (7th ed.) Citation

Osawa, M., Ueno, T., Shiozaki, T., Li, H., & Garimella, T. (2019). Safety Exposure‐Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Subjects. Journal of clinical pharmacology, 59(4), 557-565. https://doi.org/10.1002/jcph.1347

Chicago Style (17th ed.) Citation

Osawa, Mayu, Takayo Ueno, Tomomi Shiozaki, Hanbin Li, and Tushar Garimella. "Safety Exposure‐Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Subjects." Journal of Clinical Pharmacology 59, no. 4 (2019): 557-565. https://doi.org/10.1002/jcph.1347.

MLA (9th ed.) Citation

Osawa, Mayu, et al. "Safety Exposure‐Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Subjects." Journal of Clinical Pharmacology, vol. 59, no. 4, 2019, pp. 557-565, https://doi.org/10.1002/jcph.1347.